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Structural alerts are widely accepted in chemical toxicology, regulatory decision support, and 
medicinal chemistry as simple and transparent means to flag potential chemical hazards, group 
compounds into categories for read-across, or eliminate as false hits from screening campaigns (so 
called PAINS, or Pan Assay Interference compoundS. However, there has been a growing concern 
that alerts disproportionally flag too many chemicals as toxic, or active, which questions their 
reliability as toxicity (or activity) markers. Conversely, the rigorously developed and properly 
validated statistical QSAR models can accurately and reliably predict the chemical bioactivity; 
however, their use in regulatory decision support has been hampered by the lack of transparency and 
interpretability. We demonstrate that contrary to the common perception of QSAR models as “black 
boxes” they can be used to identify statistically significant chemical substructures (QSAR-based 
alerts) that influence toxicity. We show through several case studies, especially, skin sensitization 
and bioactivit profiling, that the mere presence of structural alerts in a chemical, irrespective of the 
derivation method (expert-based or QSAR-based), should be perceived at best as hypotheses of 
possible biological effects but cannot be blindly relied on for reaching conclusions about chemical 
safety or lack thereof. We will discuss a new approach that synergistically integrates structural alerts 
and rigorously validated QSAR models for both more transparent and accurate bioactivity or toxiicty 
assesment of new chemicals. 
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